https://cdaf.org/global-prevalence-of-hepatitis-c-virus-in-children-in-2018-a-modelling-study/2025-01-14T15:16:18-07:00https://cdaf.org/australia-on-track-to-achieve-who-hcv-elimination-targets-following-rapid-initial-daa-treatment-uptake-a-modeling-study/2025-01-14T19:58:26-07:00https://cdaf.org/hcv-elimination-among-people-who-inject-drugs-modelling-pre-and-post-who-elimination-era/2025-01-14T20:08:17-07:00https://cdaf.org/modeling-the-epidemiological-landscape-of-chronic-hepatitis-c-in-a-sub-saharan-african-country-what-is-needed-to-achieve-elimination-by-2030-in-burundi/2025-01-14T20:10:37-07:00https://cdaf.org/the-hepatitis-b-epidemic-and-the-urgent-need-for-cure-preparedness/2025-01-14T19:59:02-07:00https://cdaf.org/hepatitis-c-disease-burden-and-strategies-for-elimination-by-2030-in-brazil-a-mathematical-modeling-approach/2025-01-14T15:17:37-07:00https://cdaf.org/the-micro-elimination-approach-to-eliminating-hepatitis-c-strategic-and-operational-considerations/2025-01-14T20:12:37-07:00https://cdaf.org/global-regional-and-country-level-estimates-of-hepatitis-c-virus-infection-among-people-who-have-recently-injected-drugs/2025-01-14T20:00:22-07:00https://cdaf.org/nonalcoholic-fatty-liver-disease-burden-saudi-arabia-and-united-arab-emirates-2017-2030/2025-01-14T20:14:09-07:00https://cdaf.org/the-investment-case-for-hepatitis-b-and-c-in-south-africa-adaptation-and-innovation-in-policy-analysis-for-disease-program-scale-up/2025-01-14T20:16:29-07:00https://cdaf.org/hepatitis-c-the-beginning-of-the-end-key-elements-for-successful-european-and-national-strategies-to-eliminate-hcv-in-europe/2025-01-14T20:15:56-07:00https://cdaf.org/hepatitis-c-virus-dynamics-among-intravenous-drug-users-suggest-that-an-annual-treatment-uptake-above-10-would-eliminate-the-disease-by-2030/2025-01-14T20:19:43-07:00https://cdaf.org/mitigating-the-burden-of-hepatitis-c-virus-among-people-who-inject-drugs-in-belgium/2025-01-15T13:28:13-07:00https://cdaf.org/hepatitis-c-virus-infection-in-argentina-burden-of-chronic-disease/2025-01-15T13:28:33-07:00https://cdaf.org/urgent-action-to-fight-hepatitis-c-in-people-who-inject-drugs-in-europe/2025-01-15T13:27:24-07:00https://cdaf.org/disease-burden-of-hepatitis-c-in-the-austrian-state-of-tyrol-epidemiological-data-and-model-analysis-to-achieve-elimination-by-2030/2025-01-14T20:11:48-07:00https://cdaf.org/global-prevalence-treatment-and-prevention-of-hepatitis-b-virus-infection-in-2016-a-modelling-study/2025-01-14T20:15:29-07:00https://cdaf.org/hepatitis-c-virus-dynamics-among-intravenous-drug-users-suggest-that-an-annual-treatment-uptake-above-10-would-eliminate-the-disease-by-2030-2/2025-01-14T20:20:23-07:00https://cdaf.org/estimating-hcv-disease-burden-volume-4-editorial/2025-01-14T20:24:55-07:00https://cdaf.org/historical-epidemiology-of-hepatitis-c-virus-in-select-countries-volume-4/2025-01-14T20:24:15-07:00https://cdaf.org/the-present-and-future-disease-burden-of-hepatitis-c-virus-infections-with-todays-treatment-paradigm-volume-4/2025-01-14T20:23:18-07:00https://cdaf.org/strategies-to-manage-hepatitis-c-virus-infection-disease-burden-volume-4/2025-01-14T20:21:13-07:00https://cdaf.org/scenarios-to-manage-the-hepatitis-c-disease-burden-and-associated-economic-impact-of-treatment-in-turkey/2025-01-14T20:25:30-07:00https://cdaf.org/colorado-prevalence-and-incidence-of-hepatitis-c-virus-infection-a-modeling-study/2025-01-14T20:27:55-07:00https://cdaf.org/modeling-the-epidemic-of-nonalcoholic-fatty-liver-disease-demonstrates-an-exponential-increase-in-burden-of-disease/2025-01-14T20:18:03-07:00https://cdaf.org/estimates-of-the-coverage-of-diagnosis-and-treatment-for-hbv-and-hcv-infection-by-who-region-and-income-group-2015/2025-01-14T20:29:02-07:00https://cdaf.org/a-national-strategy-for-the-elimination-of-hepatitis-b-and-c-phase-two-report/2025-01-14T20:30:30-07:00https://cdaf.org/global-prevalence-and-genotype-distribution-of-hepatitis-c-virus-infection-in-2015-a-modelling-study/2025-01-15T13:24:24-07:00https://cdaf.org/hepatitis-c-virus-prevalence-and-level-of-intervention-required-to-achieve-the-who-targets-for-elimination-in-the-european-union-by-2030-a-modelling-study/2025-01-14T20:31:26-07:00https://cdaf.org/prevalence-of-non-infectious-comorbidities-in-the-hiv-positive-population-in-belgium-a-multicenter-retrospective-study/2025-01-14T20:28:30-07:00https://cdaf.org/hepatitis-c-virus-infection/2025-01-14T20:31:55-07:00https://cdaf.org/chronic-hepatitis-c-burden-and-care-cascade-in-australia-in-the-era-of-interferon-based-treatment/2025-01-14T20:34:06-07:00https://cdaf.org/global-genotype-distribution-of-hepatitis-c-viral-infection-among-people-who-inject-drugs/2025-01-15T13:25:26-07:00https://cdaf.org/historical-trends-in-the-hepatitis-c-virus-epidemics-in-north-america-and-australia/2025-01-15T13:25:05-07:00https://cdaf.org/epidemiology-disease-burden-and-treatment-strategies-of-chronic-hepatitis-c-virus-infections-in-saudi-arabia-in-the-new-treatment-paradigm-shift/2025-01-15T13:27:00-07:00https://cdaf.org/achieving-who-recommendations-for-hepatitis-c-virus-elimination-in-belgium/2025-01-15T13:30:03-07:00https://cdaf.org/mitigating-the-burden-of-hepatitis-c-virus-among-people-who-inject-drugs-in-belgium-2/2025-01-15T13:29:07-07:00https://cdaf.org/elimination-of-hepatitis-c-in-spain-adaptation-of-a-mathematical-model-based-on-the-public-health-strategic-plan-for-addressing-hepatitis-c-in-the-national-health-system/2025-01-14T20:33:31-07:00https://cdaf.org/hepatitis-b-and-c-in-the-spotlight-a-public-health-response-in-the-americas-2016/2025-01-14T20:36:43-07:00https://cdaf.org/is-elimination-of-hcv-possible-in-a-country-with-low-diagnostic-rate-and-moderate-hcv-prevalence-the-case-of-greece/2025-01-15T13:26:18-07:00https://cdaf.org/chronic-hepatitis-c-virus-hcv-burden-in-rhode-island-modelling-treatment-scale-up-and-elimination/2025-01-15T13:25:51-07:00https://cdaf.org/liver-disease-burden-of-hepatitis-c-virus-infection-in-iran-and-the-potential-impact-of-various-treatment-strategies-on-the-disease-burden/2025-01-15T13:27:49-07:00https://cdaf.org/prevalence-and-burden-of-hcv-co-infection-in-people-living-with-hiv-a-global-systematic-review-and-meta-analysis/2025-01-15T13:30:28-07:00https://cdaf.org/birth-cohort-distribution-and-screening-for-viraemic-hepatitis-c-virus-infections-in-switzerland/2025-01-15T13:34:46-07:00https://cdaf.org/disease-burden-of-chronic-hepatitis-c-in-brazil/2025-01-16T08:34:50-07:00https://cdaf.org/global-regional-and-national-comparative-risk-assessment-of-79-behavioural-environmental-and-occupational-and-metabolic-risks-or-clusters-of-risks-in-188-countries-1990-2013-a-systematic-analysi/2025-01-15T13:41:00-07:00https://cdaf.org/interferon-based-hepatitis-c-antiviral-treatment-outcomes-may-be-predicted-by-alanine-aminotransferase-levels/2025-01-16T08:31:05-07:00https://cdaf.org/global-regional-and-national-disability-adjusted-life-years-dalys-for-306-diseases-and-injuries-and-healthy-life-expectancy-hale-for-188-countries-1990-2013-quantifying-the-epidemiological-tra/2025-01-16T08:33:42-07:00https://cdaf.org/the-estimated-future-disease-burden-of-hepatitis-c-virus-in-the-netherlands-with-different-treatment-paradigms/2025-01-15T13:35:40-07:00https://cdaf.org/estimating-hcv-disease-burden-volume-3-editorial/2025-01-15T13:34:10-07:00https://cdaf.org/historical-epidemiology-of-hepatitis-c-virus-hcv-in-select-countries-volume-3/2025-01-15T13:33:02-07:00https://cdaf.org/the-present-and-future-disease-burden-of-hepatitis-c-virus-infections-with-todays-treatment-paradigm-volume-3/2025-01-15T13:32:09-07:00https://cdaf.org/strategies-to-manage-hepatitis-c-virus-infection-disease-burden-volume-3/2025-01-15T13:31:16-07:00https://cdaf.org/economic-burden-of-hepatitis-c-in-egypt-the-future-impact-of-highly-effective-therapies/2025-01-16T08:31:50-07:00https://cdaf.org/the-disease-burden-of-hepatitis-c-in-belgium-an-update-of-a-realistic-disease-control-strategy/2025-01-16T08:33:25-07:00https://cdaf.org/modeling-the-health-and-economic-burden-of-hepatitis-c-virus-in-switzerland/2025-01-16T08:32:30-07:00https://cdaf.org/hcv-infected-patients-need-access-now-to-new-direct-acting-antiviral-agents-to-avert-liver-related-deaths/2025-01-16T08:35:54-07:00https://cdaf.org/estimates-on-hcv-disease-burden-worldwide-filling-the-gaps/2025-01-16T08:40:34-07:00https://cdaf.org/historical-epidemiology-of-hepatitis-c-virus-hcv-in-select-countries-volume-2/2025-01-16T08:39:54-07:00https://cdaf.org/the-present-and-future-disease-burden-of-hepatitis-c-virus-hcv-infections-with-todays-treatment-paradigm-volume-2/2025-01-16T08:38:49-07:00https://cdaf.org/strategies-to-manage-hepatitis-c-virus-hcv-infection-disease-burden-volume-2/2025-01-16T08:37:43-07:00https://cdaf.org/hepatitis-c-disease-burden-and-strategies-to-manage-the-burden-guest-editors-mark-thursz-gregory-dore-and-john-ward/2025-01-16T08:58:16-07:00https://cdaf.org/historical-epidemiology-of-hepatitis-c-virus-hcv-in-selected-countries/2025-01-16T08:57:39-07:00https://cdaf.org/the-present-and-future-disease-burden-of-hepatitis-c-virus-hcv-infection-with-todays-treatment-paradigm/2025-01-16T08:56:59-07:00https://cdaf.org/strategies-to-manage-hepatitis-c-virus-hcv-disease-burden/2025-01-16T08:56:17-07:00https://cdaf.org/improved-treatment-on-disease-burden-of-chronic-hepatitis-c-in-new-zealand/2025-01-16T08:41:10-07:00https://cdaf.org/the-future-disease-burden-of-hepatitis-c-virus-infection-in-sweden-and-the-impact-of-different-treatment-strategies/2025-01-16T08:41:52-07:00https://cdaf.org/global-epidemiology-and-genotype-distribution-of-the-hepatitis-c-virus-infection/2025-01-16T08:45:20-07:00https://cdaf.org/burden-of-disease-and-cost-of-chronic-hepatitis-c-infection-in-canada/2025-01-16T08:55:32-07:00https://cdaf.org/enhanced-antiviral-treatment-efficacy-and-uptake-in-preventing-the-rising-burden-of-hepatitis-c-related-liver-disease-and-costs-in-australia/2025-01-16T08:44:44-07:00https://cdaf.org/modelling-the-impact-of-improving-screening-and-treatment-of-chronic-hepatitis-c-virus-infection-on-future-hepatocellular-carcinoma-rates-and-liver-related-mortality/2025-01-16T08:44:09-07:00https://cdaf.org/forecasting-the-disease-burden-of-chronic-hepatitis-c-virus-in-poland/2025-01-16T08:36:34-07:00https://cdaf.org/the-current-and-future-disease-burden-of-chronic-hepatitis-c-virus-infection-in-egypt/2025-01-16T08:51:32-07:00https://cdaf.org/innovative-strategies-for-hepatitis-c-in-belgium-integrating-treatment-efficacy-public-disease-burden-and-healthcare-costs/2025-01-16T08:54:36-07:00https://cdaf.org/hepatitis-c-epidemiology-in-belgium/2025-01-16T08:53:26-07:00https://cdaf.org/the-disease-burden-of-hepatitis-c-in-belgium-development-of-a-realistic-disease-control-strategy/2025-01-16T08:52:46-07:00https://cdaf.org/current-and-future-health-and-economic-impact-of-hepatitis-c-in-belgium/2025-01-16T08:52:12-07:00https://cdaf.org/health-policy-model-long-term-predictive-results-associated-with-the-management-of-hepatitis-c-virus-induced-diseases-in-italy/2025-01-16T08:49:55-07:00https://cdaf.org/global-regional-and-national-incidence-and-mortality-for-hiv-tuberculosis-and-malaria-during-1990-2013-a-systematic-analysis-for-the-global-burden-of-disease-study-2013/2025-01-16T08:49:16-07:00https://cdaf.org/response-to-letter-to-the-editor-strategies-to-reduce-hcv-disease-burden-and-hcv-transmission-need-different-models-as-what-works-for-end%e2%80%90stage-liver-disease-may-not-work-for-hcv-prevalence/2025-01-16T08:43:03-07:00https://cdaf.org/the-new-paradigm-of-hepatitis-c-therapy-integration-of-oral-therapies-into-best-practices/2025-01-16T08:59:13-07:00https://cdaf.org/hepatitis-c-medicines-and-diagnostics-in-the-context-of-hiv-hcv-co-infection-a-scoping-report/2025-01-16T09:02:14-07:00https://cdaf.org/the-state-of-us-health-1990-2010-burden-of-diseases-injuries-and-risk-factors/2025-01-16T12:29:27-07:00https://cdaf.org/chronic-hepatitis-c-virus-hcv-disease-burden-and-cost-in-the-united-states/2025-01-16T12:32:52-07:00https://cdaf.org/hcv-infection-prevalence-in-a-population-recruited-at-health-centers-in-jordan/2025-01-16T12:33:32-07:00https://cdaf.org/disability-adjusted-life-years-dalys-for-291-diseases-and-injuries-in-21-regions-1990-2010-a-systematic-analysis-for-the-global-burden-of-disease-study-2010/2025-01-16T13:12:20-07:00https://cdaf.org/a-comparative-risk-assessment-of-burden-of-disease-and-injury-attributable-to-67-risk-factors-and-risk-factor-clusters-in-21-regions-1990-2010-a-systematic-analysis-for-the-global-burden-of-disease/2025-01-16T12:58:50-07:00https://cdaf.org/years-lived-with-disability-ylds-for-1160-sequelae-of-289-diseases-and-injuries-1990-2010-a-systematic-analysis-for-the-global-burden-of-disease-study-2010/2025-01-16T12:49:49-07:00https://cdaf.org/economic-burden-of-hepatitis-c-associated-diseases-europe-asia-pacific-and-the-americas/2025-01-16T13:13:03-07:00https://cdaf.org/economic-burden-of-hepatitis-c-associated-diseases-in-the-united-states/2025-01-16T13:13:34-07:00https://cdaf.org/the-global-health-burden-of-hepatitis-c-virus-infection/2025-01-16T13:15:33-07:00https://cdaf.org/applying-a-system-approach-to-forecast-the-total-hepatitis-c-virus-infected-population-size-model-validation-using-us-data/2025-01-16T13:14:37-07:00https://cdaf.org/trends-and-projections-of-hepatitis-c-virus-epidemiology-in-latin-america/2025-01-16T13:17:37-07:00https://cdaf.org/a-systematic-review-of-hepatitis-c-virus-epidemiology-in-europe-canada-and-israel/2025-01-16T13:17:08-07:00https://cdaf.org/a-systematic-review-of-hepatitis-c-virus-epidemiology-in-asia-australia-and-egypt/2025-01-16T13:16:02-07:00https://cdaf.org/modeling-nafld-disease-burden-in-china-france-germany-italy-japan-spain-united-kingdom-and-united-states-for-the-period-2016-2030/2025-01-14T20:13:42-07:00https://cdaf.org/a-tool-to-measure-the-impact-of-inaction-toward-elimination-of-hepatitis-c-a-case-study-in-korea/2025-01-14T15:10:33-07:00https://cdaf.org/a-tool-to-measure-the-economic-impact-of-hepatitis-b-elimination-a-case-study-in-saudi-arabia/2025-01-14T14:58:17-07:00https://cdaf.org/covid-19-on-global-hcv-elimination-efforts/2025-01-14T15:01:28-07:00https://cdaf.org/progress-toward-hepatitis-b-and-hepatitis-c-elimination-using-a-catalytic-funding-model-tashkent-uzbekistan-december-6-2019-march-15-2020/2025-01-14T15:00:04-07:00https://cdaf.org/burden-of-nonalcoholic-fatty-liver-disease-in-canada-2019-2030-a-modelling-study/2025-01-14T15:08:33-07:00https://cdaf.org/nonalcoholic-fatty-liver-disease-burden-australia-2019-2030/2025-01-14T15:15:03-07:00https://cdaf.org/modelling-nafld-disease-burden-in-four-asian-regions-2019-2030/2025-01-14T15:14:23-07:00https://cdaf.org/assessment-of-treatment-strategies-to-achieve-hepatitis-c-elimination-in-canada-using-a-validated-model/2025-01-14T15:09:52-07:00https://cdaf.org/nonalcoholic-fatty-liver-disease-burden-switzerland-2018-2030/2025-01-14T15:16:59-07:00https://cdaf.org/editorial-increasing-burden-of-nonalcoholic-fatty-liver-disease-a-call-to-action-authors-reply/2025-01-14T15:05:46-07:00https://cdaf.org/forecasting-hepatitis-c-liver-disease-burden-on-real-life-data-does-the-hidden-iceberg-matter-to-reach-the-elimination-goals/2025-01-14T20:09:39-07:00https://cdaf.org/strategies-to-eliminate-hepatitis-c-in-croatia-a-modelling-study/2025-01-14T14:57:01-07:00https://cdaf.org/modelling-hepatitis-b-virus-infection-and-impact-of-timely-birth-dose-vaccine-a-comparison-of-two-simulation-models/2025-01-14T15:00:48-07:00https://cdaf.org/a-micro-elimination-approach-to-addressing-hepatitis-c-in-turkey/2025-01-14T15:13:30-07:00https://cdaf.org/optimization-of-hepatitis-c-virus-screening-strategies-by-birth-cohort-in-italy/2025-01-14T15:12:02-07:00https://cdaf.org/tailored-screening-and-dedicated-funding-for-direct-acting-antiviral-drugs-how-to-keep-italy-on-the-road-to-hepatitis-c-virus-elimination/2025-01-14T15:04:21-07:00https://cdaf.org/do-the-most-heavily-burdened-countries-have-the-right-policies-to-eliminate-viral-hepatitis-b-and-c/2025-01-14T15:03:30-07:00https://cdaf.org/the-hep-core-policy-score-a-european-hepatitis-c-national-policy-implementation-ranking-based-on-patient-organization-data/2025-01-14T15:02:57-07:00https://cdaf.org/the-case-for-simplifying-and-using-absolute-targets-for-viral-hepatitis-elimination-goals/2025-01-14T14:59:00-07:00https://cdaf.org/global-epidemiology-of-viral-hepatitis/2025-01-14T15:07:18-07:00https://cdaf.org/covid-19-and-global-hcv-elimination-efforts/2025-01-14T14:48:00-07:00https://cdaf.org/hepatitis-c-elimination-in-sweden-progress-challenges-and-opportunities-for-growth-in-the-time-of-covid%e2%80%9019/2025-01-14T14:41:04-07:00https://cdaf.org/global-prevalence-of-hepatitis-c-virus-in-women-of-childbearing-age-in-2019-a-modelling-study/2025-01-14T14:51:51-07:00https://cdaf.org/estimating-the-health-impact-of-vaccination-against-ten-pathogens-in-98-low-income-and-middle-income-countries-from-2000-to-2030-a-modelling-study/2025-01-14T14:48:48-07:00https://cdaf.org/the-global-nafld-policy-review-and-preparedness-index-are-countries-ready-to-address-this-silent-public-health-challenge/2025-01-14T14:37:21-07:00https://cdaf.org/progress-towards-achieving-viral-hepatitis-b-and-c-elimination-in-the-asia-and-pacific-region-results-from-modelling-and-global-reporting/2025-01-14T14:36:23-07:00https://cdaf.org/hcv-disease-burden-and-population-segments-in-switzerland/2025-01-14T14:38:08-07:00https://cdaf.org/epidemiology-natural-history-and-outcomes-of-primary-sclerosing-cholangitis-a-systematic-review-of-population-based-studies/2025-01-14T14:38:56-07:00https://cdaf.org/lives-saved-with-vaccination-for-10-pathogens-across-112-countries-in-a-pre-covid-19-world/2025-01-14T14:40:02-07:00https://cdaf.org/progress-towards-hepatitis-c-virus-elimination-in-high-income-countries-an-updated-analysis/2025-01-14T14:53:09-07:00https://cdaf.org/the-cost-effectiveness-of-hepatitis-c-virus-elimination-in-low-and-middle-income-countries/2025-01-14T14:54:38-07:00https://cdaf.org/global-change-in-hepatitis-c-virus-prevalence-and-cascade-of-care-between-2015-and-2020-a-modelling-study/2025-01-14T19:55:39-07:00https://cdaf.org/opportunistic-co-screening-for-hcv-and-covid-19-relatedservices-a-creative-response-with-a-need-for-thoughtful-reflection/2025-01-14T14:27:36-07:00https://cdaf.org/cost-effectiveness-modelling-of-birth-and-infant-dose-vaccination-against-hepatitis-b-virus-in-ontario-from-2020-to-2050/2025-01-14T20:05:35-07:00https://cdaf.org/modeling-hcv-elimination-recovery-following-the-covid-19-pandemic-in-the-united-states-pathways-to-regain-progress-2/2025-01-14T20:06:26-07:00https://cdaf.org/ten-years-countdown-to-hepatitis-c-elimination-in-belgium-a-mathematical-modeling-approach/2025-01-14T14:28:40-07:00https://cdaf.org/an-open-letter-to-gavi-hepatitis-b-birth-dose-vaccine-cant-wait/2025-01-14T20:06:39-07:00https://cdaf.org/global-reporting-of-progress-towards-elimination-of-hepatitis-b-and-hepatitis-c/2025-01-14T20:04:15-07:00https://cdaf.org/impact-of-expanding-hepatitis-b-treatment-guidelines-a-modelling-and-economic-impact-analysis/2025-01-14T20:07:22-07:00https://cdaf.org/evidence-for-benefits-of-early-treatment-initiation-for-chronic-hepatitis-b/2025-01-14T20:04:02-07:00https://cdaf.org/the-payer-license-agreement-or-netflix-model-for-hepatitis-c-virus-therapies-enables-universal-treatment-access-lowers-costs-and-incentivizes-innovation-and-competition/2025-01-14T20:04:28-07:00https://cdaf.org/cost-effectiveness-and-economic-investment-to-eliminate-chronic-hepatitis-c-in-mexico/2025-01-14T20:04:55-07:00https://cdaf.org/hepatitis-c-prevalence-and-elimination-planning-in-pakistan-a-bottom-up-approach-accounting-for-provincial-variation/2025-01-14T20:05:21-07:00https://cdaf.org/viral-hepatitis-elimination-challenges-in-low-and-middle-income-countries-uzbekistan-hepatitis-elimination-program-uhep/2025-01-14T20:05:58-07:00https://cdaf.org/the-current-and-future-burden-of-hepatitis-b-in-switzerland-a-modelling-study/2025-01-14T20:03:48-07:00https://cdaf.org/polaris-observatory-supporting-informed-decision-making-at-the-national-regional-and-global-levels-to-eliminate-viral-hepatitis/2025-01-14T14:29:20-07:00https://cdaf.org/cost-effectiveness-of-treating-all-hepatitis-b-positive-individuals-in-the-united-states/2025-01-14T20:03:29-07:00https://cdaf.org/the-impact-of-immigration-on-hepatitis-b-burden-in-the-united-states-a-modelling-study/2025-01-14T20:02:32-07:00https://cdaf.org/modelling-the-microelimination-of-chronic-hepatitis-c-in-the-canton-of-bern-switzerland-reaching-the-swiss-hepatitis-strategy-goals-despite-the-impact-of-the-covid-19-pandemic/2025-01-14T20:07:07-07:00https://cdaf.org/updated-epidemiology-of-hepatitis-c-virus-infections-and-implications-for-hepatitis-c-virus-elimination-in-germany/2025-01-14T14:29:01-07:00https://cdaf.org/now-is-the-time-to-scale-up-birth-dose-hepatitis-b-vaccine-in-low-and-middle-income-countries/2025-01-14T20:05:07-07:00https://cdaf.org/securing-wider-eu-commitment-to-the-elimination-of-hepatitis-c-virus/2025-01-14T20:06:53-07:00https://cdaf.org/adjusted-estimate-of-the-prevalence-of-hepatitis-delta-virus-in-25-countries-and-territories/2025-01-14T20:02:11-07:00https://cdaf.org/global-prevalence-cascade-of-care-and-prophylaxis-coverage-of-hepatitis-b-in-2022-a-modelling-study/2025-01-14T20:01:49-07:00https://cdaf.org/hepatitis-c-screening-in-lithuania-first-year-results-and-scenarios-for-achieving-who-elimination-targets/2025-01-14T20:01:18-07:00https://cdaf.org/the-economic-argument-for-hepatitis-b-treatment-simplification-and-expansion/2025-01-14T20:00:54-07:00https://cdaf.org/modeling-the-health-and-economic-impact-of-pharmacologic-therapies-for-masld-in-the-united-states/2026-05-28T21:37:51-06:00https://cdaf.org/the-disease-and-economic-burden-of-hbv-and-hcvin-ethiopia/2026-05-28T21:17:24-06:00https://cdaf.org/modelling-micro-elimination-third-trimester-tenofovir-prophylaxis-for-perinatal-transmission-of-hepatitis-b-in-the-remote-dolpa-district-of-nepal/2026-05-28T21:43:42-06:00https://cdaf.org/closing-the-gap-in-hcv-care-strategic-collaboration-between-industry-academic-community-and-nonprofit-researchers/2026-05-31T11:04:46-06:00https://cdaf.org/the-current-burden-of-hepatitis-b-in-the-united-states-a-state-territorial-and-county-modelling-analysis/2026-05-28T23:36:07-06:00https://cdaf.org/estimating-the-impact-of-displacement-from-ukraine-on-hbv-and-hcv-prevalence-among-migrants-in-the-european-union-2024-a-modeling-study/2026-05-28T23:42:16-06:00https://cdaf.org/global-hbv-disease-burden-and-current-care-gaps/2026-05-28T23:47:47-06:00https://cdaf.org/global-progress-toward-viral-hepatitis-elimination/2026-05-31T11:05:24-06:00https://cdaf.org/number-of-people-treated-for-hepatitis-c-virus-infection-in-2014-2023-and-applicable-lessons-for-new-hbv-and-hdv-therapies/2026-05-28T23:59:01-06:00https://cdaf.org/a-call-to-reclassify-the-delta-hepatitis-virus-as-an-orphan-disease/2026-05-29T00:08:03-06:00https://cdaf.org/the-burden-of-chronic-hepatitis-b-and-c-in-2022-and-progress-towards-elimination-a-global-report/2026-05-29T00:12:33-06:00https://cdaf.org/bulevirtide-for-chronic-hepatitis-delta-from-clinical-trials-to-real-life-data-an-expert-opinion-report/2026-05-31T11:05:45-06:00https://cdaf.org/from-targets-to-real-world-impact-a-review-of-models-of-care-for-chronic-hbv-and-hcv-in-europe/2026-06-03T15:05:41-06:00https://cdaf.org/implementing-sustainable-liver-health-in-europe-a-second-easl-lancet-commission/2026-06-03T15:15:30-06:00